Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
US12065426B2 · kind B2 · utility
0Cited by
4References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 5, 2019 |
| Grant date | Aug 20, 2024 |
| Priority date | — |
| Expiry date | Feb 3, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition comprising the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.